- Everyday Alpha
- Posts
- Tap Into This Credit Card Company’s Earnings Strength With This Plan
Tap Into This Credit Card Company’s Earnings Strength With This Plan
This mega-cap financial is doing the boring kind of great. More purchases, steady travel, and a machine that earns a little on every tap.
Start with a small slice on calm red days, then add only when spending, new cards, and profit keep rising together.

Founders need better information
Get a single daily brief that filters the noise and delivers the signals founders actually use.
All the best stories — curated by a founder who reads everything so you don't have to.
And it’s totally free. We pay to subscribe, you get the good stuff.

Never Miss a Stock Alert Again!
We now send our daily picks via SMS too — so you’ll get the same high-conviction ideas, even if you miss the email.

Nvidia | NVDA

Price: $207.32
Nvidia reminded everyone it is not just a chip designer in Taiwan anymore.
The newest graphics chips are now being produced and assembled in Arizona, which is a tidy answer to supply worries and a friendly message to policy makers.
Demand remains heavy, partners are lining up, and new projects span everything from giant computers to future wireless networks.
That breadth keeps the story from being a one-trick pony tied to one customer or one country.
The flip side is valuation that already expects greatness, plus export rules that can shift the map overnight.
Keep your eyes on three basics. Delivery of the newest chips on time, clear orders from large customers, and signs that new platforms like telecom gear actually ship in volume.
If those boxes fill, time in the name can matter more than timing the name. Start small on red days and let confirmed progress earn each add.
If headlines get louder than the numbers, skim and wait for the next proof point.
Why it matters to you: Owning the building blocks of modern computing pays best when shipments keep landing.

Regeneron | REGN

Price: $653.01
This quarter came through with higher profit and steady revenue growth, which is what you want from a science shop that already sells real medicines.
Flagship drugs continued to carry weight, and management is leaning into manufacturing capacity and late-stage studies that could refresh growth over the next few years.
The market liked the beat, but the bigger question is what the next wave of treatments can add on top of today’s lineup.
Drug pricing noise and the usual regulatory maze still live in the background, so size with patience.
Watch three things. Ongoing sales from the biggest products, clean milestones from late-stage trials, and any hiccups in factories that could slow supply.
If those stay on track, the story gets steadier and the cash machine gets louder.
Use market weakness to build a starter, then add on real data, not just conference slides. Trim if the stock races ahead of the pipeline.
Why it matters to you: Proven products plus a funded pipeline is a friendly mix for long-term compounding.

Don’t Miss Out (Sponsored)
Some stocks don’t just rise — they explode.
Market experts have narrowed down the field to 5 exceptional companies poised for strong upside potential in the coming months.
These picks come from deep analysis of earnings strength, market momentum, and institutional demand — factors that have historically led to triple-digit returns.
Previous reports from this research team have uncovered stocks that delivered +175%, +498%, even +673%.¹
Now, the latest report reveals five new opportunities — free to access, but only for a limited time.
[Unlock the 5 Stocks Set to Double – Free Until Midnight]
*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.

United Parcel Service | UPS

Price: $97.41
Cost cuts are not exciting to talk about, but they move the needle.
UPS has removed tens of thousands of jobs, closed dozens of sites, and refocused on higher-margin routes like health care logistics and small business services.
The latest update showed stronger profit than expected and a better holiday outlook, which is the kind of one-two that can reset sentiment.
The open question is how much of the rebound is from cuts versus a true pickup in packages. Fuel, labor, and pricing still swing the story.
Stick to a practical scorecard. Daily package trends through peak season, profit per package, and any signs that health care and small business mix is lifting margins.
If the company can grow profit without growing miles driven, the math gets friendlier fast.
Build positions on quiet days, then press only if the next report confirms better margins and a clean holiday run-rate.
Why it matters to you: Leaner routes and richer mix can turn a tough year into a repair year without heroics.

MSCI | MSCI

Price: $567.69
Indexes and data are the pipes of investing, and MSCI owns some important ones.
Profit topped expectations even as revenue landed a touch light, helped by tight costs and steady growth in recurring fees.
Management is folding more automation and artificial intelligence into the toolkit, which should keep expenses in check and open the door for new products like private credit models.
The company also has fresh room to buy back shares, which adds a quiet tailwind when results cooperate.
Your checklist stays clean. Look for organic revenue growth near the high single digits, firm renewal rates across big asset managers, and proof that new products win real clients. If costs fall while new lines scale, earnings can outrun sales.
Start small on dips and add when renewals, margins, and product traction improve together. If the stock runs hot without fresh wins, trim a little and let it come to you.
Why it matters to you: Sticky data fees with new product optionality can compound through many market cycles.

Visa | V

Price: $341.25
Payments are a scale game and Visa has the field position.
Recent results showed double-digit revenue growth, strong purchase activity, and solid cross-border traffic, which is just a fancy way of saying people are spending at home and abroad.
That mix matters because every tap and chip insert drops a few pennies into the jar.
The company also keeps rolling out safer checkout tools for banks and stores, which helps add new cards and keep fraud in check.
The one soft spot was a slight dip in pre-tax margin, so we want to see expenses behave as volume climbs.
Your checklist is simple. Watch spending growth, cross-border strength, and cost control. If those three keep moving the right way, the stock can grind higher without drama.
Build on dips, then add when the next update confirms the trend. Trim a little only if price sprints far ahead of the numbers.
Why it matters to you: A tiny toll on trillions of purchases can compound for years with fewer surprises.

Poll: Which would you rather automate? |

Stat of the Day: 20%
Washington and Beijing may trade a tariff cut for a stronger crackdown on fentanyl chemicals.
A lower rate would take some heat off import costs and could ease a bit of price pressure in goods tied to China.
Final Take:
Today’s basket mixes toll collectors, chip muscle, a steady lab, a leaner delivery giant, and a data toll road. Same plan as always.
Buy red, size to your sleep level, and let better numbers earn your adds. When headlines get loud, follow your checklist and let price come to you rather than chasing the crowd.
Best Regards,
—Noah Zelvis
Everyday Alpha



